Non-segmental Vitiligo Clinical Trial
Official title:
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation
| Verified date | August 2023 |
| Source | Aswan University Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.
| Status | Active, not recruiting |
| Enrollment | 150 |
| Est. completion date | March 13, 2024 |
| Est. primary completion date | February 13, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Patients with non-segmental vitiligo of any age and gender. Exclusion Criteria: - History of vitiligo treatment with topical, systemic or biological agents prior to the study for at least 3 weeks. - Pregnancy and lactation. - Infections - Patients with other autoimmune diseases. - Patients with chronic diseases: cardiac diseases, hepatic disorders, hematologic disease, chronic renal failure or malignancies. |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | faculty of medicine, Aswan University | Aswan | Aswan Governorate |
| Lead Sponsor | Collaborator |
|---|---|
| Shaimaa Fawzy Abdel-rady Abdel-latif |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | serum TWEAK in vitiligo | measurement of serum Tumor necrosis factor weak inducer of apoptosis (TWEAK)"pg/ml"; in vitiligo patients before and after treatment with NB-UVB, Latanoprost and their combination, all in comparison with healthy individuals, using ELISA (enzyme-linked immunosorbent assay) | 3months | |
| Secondary | treatment of vitiligo | clinical evaluation: Assessment of the disease severity in non-segmental vitiligo will be performed by using vitiligo area severity index (VASI score) before and after treatment with NB-UVB, latanoprost application applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches, or combination of both of them. Patients will be photographed at baseline and after 3 months of regular treatment by using high resolution digital camera conon EOS 1300D 18 megapixels (made in Taiwan), photography will be done in standard light and distance. | 3 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04052425 -
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
|
Phase 3 | |
| Completed |
NCT04057573 -
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
|
Phase 3 | |
| Completed |
NCT04942860 -
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo
|
Phase 3 | |
| Recruiting |
NCT06113328 -
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
|
Phase 2 | |
| Recruiting |
NCT01377077 -
Punchgrafting Techniques for Vitiligo
|
Phase 4 | |
| Completed |
NCT04927975 -
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
|
Phase 2 | |
| Completed |
NCT04487860 -
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
|
Phase 2 | |
| Terminated |
NCT03022019 -
ReNovaCell in Non-segmental Vitiligo
|
N/A | |
| Completed |
NCT03247400 -
The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05990309 -
ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO
|
N/A |